Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Down 15.6% in March

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 11,135 shares, a drop of 15.6% from the March 15th total of 13,194 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Hansa Biopharma AB (publ) Price Performance

Shares of Hansa Biopharma AB (publ) stock opened at $2.90 on Friday. The company has a fifty day moving average price of $2.90 and a 200 day moving average price of $3.21. Hansa Biopharma AB has a twelve month low of $2.73 and a twelve month high of $4.58.

Analyst Ratings Changes

HNSBF has been the topic of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Hansa Biopharma AB (publ) in a report on Thursday, February 12th. Wedbush initiated coverage on shares of Hansa Biopharma AB (publ) in a report on Wednesday, January 7th. They issued an “outperform” rating on the stock. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy”.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.